NCT01041235View on ClinicalTrials.gov

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2011

Conditions
Solid TumorBreast CancerOvarian CancerPancreatic CancerNon-Small Cell Lung
Interventions
DRUG

ATI-1123 (active drug = docetaxel)

Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV

Trial Locations (2)

75230

Mary Crowley Cancer Research Centers (MCCRC), Dallas

78229

Cancer Therapy and Research Center (CTRC), San Antonio

Sponsors
All Listed Sponsors
lead

Azaya Therapeutics, Inc.

INDUSTRY

NCT01041235 - Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies | Biotech Hunter | Biotech Hunter